In vitro angiomodulatory activity of sera from type 2 diabetic patients with background retinopathy

Journal of Physiology and Pharmacology

Volumn 56, Issue SUPPL. 4, 2005, Pages 65-70

  Chorostowska Wynimko, J ^a   Skopinski P ^b,c   Szaflik, J ^b   Partyka, I ^b   Duda Krol B ^b   Anuszewska, E ^d   Skopinska Rozewska E ^b  

^a NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

Diabetes type 2; Endothelial proliferation; IGF 1; IL 18; Retinopathy; VEGF

Indexed keywords

ANGIOGENESIS MODULATOR; INTERLEUKIN 18; SOMATOMEDIN C; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CAPILLARY; CELL ACTIVITY; CELL PROLIFERATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SKIN TEST; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ANGIOGENIC PROTEINS; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-18; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 31344435429     PISSN: 08675910     EISSN: 08675910     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
2. Verma D. Pathogenesis of diabetic retinopathy: the missing link? Med Hypotheses 1993; 41: 205-210.
3. Paques M, Massin P, Gaudric A. Growth factors and diabetic retinopathy. Diabetes Metab 1997, 23, 125-130.
4. Grant MB, Afzal A, Spoerri P et al. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004; 13: 1275-1293.
5. Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 2003; 22: 721-748.
6. Skopiński P, Duda-Król B, Lipińska A et al. Aktywność angiogenna i stȩzenie VEGF w surowicach chorych na cukrzycȩ powikłana̧ retionpatia̧ prosta̧. Klinika Oczna 2004; 106(suppl 3): 421- 423.
7. Skopiński P, Rogala E, Duda-Król B et al. Increased interleukin 18 (IL-18) content and angiogenic activity of sera from diabetic patients with background retinopathy. J Diabetes Compl 2005 (in print).
8. Skopiński P, Szaflik J, Duda-Król B et al. Suppression of angiogenic activity of sera from diabetic patients with non-proliferative retinopathy by compounds of herbal origin and sulindac sulfone. Int J Mol Med 2004; 14: 707-714.
9. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
10. Anuszewska EL, Gruber BM, Koziorowska JH. Studies on adaptation to adriamycin in cells pretreated with hydrogen peroxide. Biochem Pharmacol 1997; 54: 597-603.
11. Yancopoulos GD, Davis S, Gale NW et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
12. Mukhopadhyay D, Zeng H, Bhattacharya R. Complexity in the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-receptors signaling. Mol Cell Biochem 2004; 264: 51-61.
13. Thurston G, Suri C, Smith K et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999; 286: 2511-2514.
14. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1997; 359: 843-845.
15. Lu M, Adamis AP. Vascular endothelial growth factor gene regulation and action in diabetic retinopathy. Ophthalmol Clin North Am 2002; 15: 69-79.
16. Dandona P., Aljada A., Mohanty P et al. Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9. Diabetes Care 2003; 26: 3310-3314.
17. Coughlin C, Salhany K, Wysocka M et al. Interleukin -12 and interleukin 18 synergistically induce murine tumor regression involves inhibition of angiogenesis. J Clin Invest 1998; 101: 1441-1452.
18. Park CC, Morel JC, Amin M.A et al. Evidence of IL-18 as a novel angiogenic factor. J Immunol 2001; 167:1644-1653.
19. Kampfer H, Paulukat J, Muhl H et al. Lack of interferon-gamma production despite the presence of interleukin-18 during cutaneous wound healing. Mol Med 2000; 6: 1016-1027.
20. Chantelau E. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 1998; 82: 725-730.
21. Spoerri PE, Caballero S, Wilson SH et al. Expression of IGFBP-3 by human retinal endothelial cell cultures: IGFBP-3 involvement in growth inhibition and apoptosis. Invest Ophthalmol Visual Sci 2003; 44: 365-369.